)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
scPharmaceuticals (SCPH) investor relations material
scPharmaceuticals Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary7 Aug, 2025
Executive summary
Net revenue reached $16M in Q2 2025, up 99% year-over-year, driven by strong FUROSCIX demand, commercial execution, and expanded CKD indication.
20,200 FUROSCIX doses filled in Q2, a 117% increase year-over-year and 45% sequential growth, with cardiology and nephrology as key contributors.
Launch in nephrology in late April 2025 showed rapid prescriber uptake and higher doses per prescription.
Development of an 80mg/1mL autoinjector is underway, with sNDA submission on track for Q3 2025, aiming to reduce COGS and environmental impact.
FDA granted 3-year exclusivity for FUROSCIX, preventing approval of competing subcutaneous furosemide products until October 2025.
Financial highlights
Q2 2025 product revenues were $16M, up from $8.1M in Q2 2024; cost of product revenues rose to $5M from $2.3M.
Net loss for Q2 2025 was $18M, compared to $17.1M in Q2 2024; net loss per share was $0.34.
Cash and cash equivalents at June 30, 2025, were $40.8M, down from $75.5M at year-end 2024.
Gross margin for Q2 2025 was approximately 69%.
Operating expenses for Q2 2025 were $30.3M, up from $22.5M in Q2 2024, driven by increased R&D and SG&A costs.
Outlook and guidance
Anticipates continued growth in nephrology and IDN segments, with further acceleration in Q3 and Q4.
Expects fill rates and prescription volumes to increase through 2025, supported by lower patient co-pays and Medicare Part D redesign.
sNDA for the autoinjector on track for Q3 2025, expected to reduce COGS by ~75% and boost penetration.
Management expects continued operating losses as commercialization expands and R&D investment continues.
Existing cash and available funds expected to cover commitments for at least the next 12 months.
How is the nephrology launch progressing?
Assess impact of Part D dynamics on growth.
When is the ASM program expected to roll out?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next scPharmaceuticals earnings date
Q3 202512 Nov, 2025
Next scPharmaceuticals earnings date
Q3 202512 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
scPharmaceuticals Inc. is a pharmaceutical company focused on developing and commercializing products for subcutaneous drug delivery. The company specializes in creating innovative solutions that enable the administration of therapies outside of traditional healthcare settings, aiming to improve patient outcomes and reduce healthcare costs. scPharmaceuticals' products are designed for self-administration, offering convenience for patients with chronic conditions. Its approach integrates drug formulations with advanced delivery technologies to provide effective treatments across a range of therapeutic areas. The company is headquartered in Burlington, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage